Tandem Mass Spectrometry Mikael Pedersen, Jens Hinge Andersen

Total Page:16

File Type:pdf, Size:1020Kb

Tandem Mass Spectrometry Mikael Pedersen, Jens Hinge Andersen Confirmatory analysis of steroids in muscle using liquid chromatography - tandem mass spectrometry Mikael Pedersen, Jens Hinge Andersen To cite this version: Mikael Pedersen, Jens Hinge Andersen. Confirmatory analysis of steroids in muscle using liq- uid chromatography - tandem mass spectrometry. Food Additives and Contaminants, 2011, pp.1. 10.1080/19440049.2010.549153. hal-00671233 HAL Id: hal-00671233 https://hal.archives-ouvertes.fr/hal-00671233 Submitted on 17 Feb 2012 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Food Additives and Contaminants For Peer Review Only Confirmatory analysis of steroids in muscle using liquid chromatography – tandem mass spectrometry Journal: Food Additives and Contaminants Manuscript ID: TFAC-2010-345.R1 Manuscript Type: Original Research Paper Date Submitted by the 09-Dec-2010 Author: Complete List of Authors: Pedersen, Mikael; DTU Food, Food Chemistry Andersen, Jens; DTU Food, Food Chemistry Methods/Techniques: Chromatography - LC/MS, Method validation Additives/Contaminants: Veterinary drug residues - anabolic steroids Food Types: Animal products – meat http://mc.manuscriptcentral.com/tfac Email: [email protected] Page 1 of 23 Food Additives and Contaminants 1 2 3 4 5 1 Confirmatory analysis of steroids in muscle using liquid chromatography – 6 7 2 8 tandem mass spectrometry 9 10 3 11 12 4 Mikael Pedersen and Jens Hinge Andersen 13 14 15 5 16 For Peer Review Only 17 6 National Food Institute (DTU-FOOD), Mørkhøj Bygade 19, DK-2860 Søborg, Denmark 18 19 20 7 21 22 8 Abstract: 23 24 9 A method is described for screening and confirmation of synthetic and endogenous steroids in 25 26 27 10 muscle tissue. The method is sensitive, selective, rapid and the consumption of organic solvents is 28 29 11 low, compared to previously published methods. The procedure involves hydrolysis, defattening 30 31 12 with heptane and final clean up with SPE using C18 cartridge. After filtration the analytes are 32 33 34 13 analysed by LC/MS/MS, and quantification is performed using deuterated internal standards. 35 36 14 Decision limits (CC α) varied from 0.02 to 0.33 µg kg -1 and the detection capabilities (CC β) were < 37 38 -1 39 15 0.50 µg kg . The mean within-laboratory reproducibility ranged from 5 – 22% (%RSD IR ). 40 41 16 Endogenous steroids (ex. testosterone, epitestosterone and androstenedione), have been included in 42 43 17 the method, to provide insights into the levels of these steroids as findings of these endogenous 44 45 46 18 steroids have been made several times during the period where analysis has been made of imported 47 48 19 meat. 49 50 51 20 52 21 Keywords: Steroids, LC-MS/MS, Muscle, Method validation, LC-TOFMS, Import control 53 22 54 55 23 Introduction 56 57 58 24 The use of androgen steroids is forbidden for fattening purposes in the European Community [1]. 59 60 25 The most suitable matrices for control of abuse is often urine, faeces, plasma and kidney fat, but for 1 http://mc.manuscriptcentral.com/tfac Email: [email protected] Food Additives and Contaminants Page 2 of 23 1 2 3 4 5 26 control of abuse of these compounds in import from third countries to the EU, these matrices are not 6 7 27 available. Therefore a sensitive and specific method for screening and confirmation of these 8 9 28 substances in muscle, has been developed. In 2007 Denmark imported 6300 tons of beef directly 10 11 12 29 from third countries (primarily South America and Australia) corresponding to app. 5% of beef 13 14 30 consumed in Denmark. 15 16 31 For Peer Review Only 17 18 -1 19 32 Since the European Commission has set 1 µg kg as the recommended concentrations for most 20 21 33 steroids in muscle tissue [2] a very sensitive method has to be used and it must be in compliance 22 23 24 34 and validated in accordance with the criteria of the Commission Decision 2002/657/EC [3]. 25 26 35 A confirmatory method has been developed for the determination of chlormadinone acetate, 27 28 36 megestrol acetate, melengestrol acetate, medroxyprogesterone acetate, methyltestosterone, α/β- 29 30 31 37 boldenone, methylboldenone, α/β -trenbolone, α/β-nortestosterone, altrenogest, testosterone, 32 33 38 epitestosterone, androstenedione and clostebolacetate (screening only) in muscle from bovine. The 34 35 36 39 steroids represent both gestagens and androgens and both synthetic and endogenous steroids have 37 38 40 been included. The method has the advantages that the amount of organic solvents consumed is 39 40 41 very low, no evaporation steps are needed and because of appropriate cleanup and reduced amount 41 42 43 42 of sample material, the matrix effect is low. Since 2007, analysis for steroids in meat from third 44 45 43 countries has been included in the Danish residue plan and the developed method is part of the 46 47 48 44 flexible accreditation our laboratory has been assigned by the Danish Accreditation and Metrology 49 50 45 Fund - DANAK [4]. As a consequence of the survey on the use of veterinary medicinal products in 51 52 46 third countries prepared in 2009 [5], the substances altrenogest and clostebolacetat were included in 53 54 55 47 the method. Clostebolacetate, though, was not included in the accreditation because some criteria 56 57 48 regarding confirmation was not fulfilled. 58 59 49 60 2 http://mc.manuscriptcentral.com/tfac Email: [email protected] Page 3 of 23 Food Additives and Contaminants 1 2 3 4 5 50 The procedure involves hydrolysis, defattening with heptane, clean up with SPE using C18 6 7 51 cartridges and final filtration. Analytes were analysed using liquid chromatography (LC) coupled 8 9 52 with tandem mass spectrometry (MS 2), and quantification was performed using spiked standards in 10 11 12 53 combination with deuterated internal standards. Two ion transitions were monitored for each 13 14 54 analyte. The decision limits (CC α) and detection capabilities (CC β) were well below the 15 16 For Peer Review-1 Only 17 55 recommended concentration which is set at 1 µg kg . The mean within-laboratory reproducibility 18 19 56 ranged from 5 to 22% (%RSD IR ). The method is sensitive and reliable and has been used for import 20 21 57 control during the last two years. In addition to the detection and quantification by LC-MS/MS, 22 23 24 58 detection by exact mass measurement using time-of-flight mass spectrometry (LC-TOFMS) has 25 26 59 been demonstrated. The three endogenous steroids testosterone, epitestosterone and 27 28 29 60 androstenedione, have been included in the method to get knowledge about the levels of these 30 31 61 steroids and findings of these steroids have been made several times. A fractional factorial design 32 33 62 was used to evaluate the performance of the method when introducing changes in possible critical 34 35 36 63 factors. 37 38 39 64 Materials and methods 40 41 42 65 Materials and reagents 43 66 All reagents were of analytical or HPLC grade and supplied by Merck (Darmstadt, Germany) 44 45 67 and Rathburn Chemicals (Walkerburn, Scotland). Water was ultra-purified using a Maxima 46 47 48 68 purification system from USF Elga (Bucks, UK). Protease Type VIII from B. Licheniformis was 49 50 69 from Sigma-Aldrich (St. Louis, MO, USA). Medroxyprogesteronacetate (MPA), Megestrolacetate 51 52 70 (MGA), Chlormadinonacetate (CMA), Methyltestosterone (MT), β-Nortestosterone (BNO), 53 54 55 71 Testosterone (TES), epitestosterone (ETE), Androstenedione (ASD), Clostebolacetate (CLAc) and 56 57 72 Altrenogest (ALTR) were purchased from Sigma-Aldrich, Melengestrolacetate (MLA) was 58 59 60 73 purchased from Steraloids Inc. (Newport, USA), α-Trenbolon (ATR) was bought from LGC 3 http://mc.manuscriptcentral.com/tfac Email: [email protected] Food Additives and Contaminants Page 4 of 23 1 2 3 4 5 74 PromoChem (National Analytical Reference Laboratory, Australia), Methylboldenon (MBO), α- 6 7 75 Boldenon (ABO), β-Boldenon (BBO), β-Trenbolon (BTR) and α-Nortestosteron (ANO), 8 9 10 76 Medroxyprogesteronacetate-d3 (MPA-d3), Megestrolacetate-d3 (MGA-d3), Melengestrolacetate-d3 11 12 77 (MLA-d3), Testosteron-d2 (TES-d2), Methyltestosteron-d3 (MT-d3), β-Boldenone-d3 (BBO-d3), 13 14 15 78 Methylboldenone-d3 (MBO-d3), β-Nortestosteron-d3 (BNO-d3) and β-Trenbolon-d2 (BTR-d2) were 16 For Peer Review Only 17 79 purchased from RIVM (Bilthoven, The Netherlands). Stock solutions of each compound were 18 19 80 prepared separately in ethanol at concentrations of 1 mg mL -1. Stock solutions of internal standards, 20 21 22 81 however, were prepared by reconstitution of ampoules containing a fixed amount of material with 23 24 82 ethanol at a concentration of 0.1 mg mL -1. Stock solutions were stored at –18 °C until use for up to 25 26 -1 27 83 3 year. A final working solution containing all the compounds at 0.1 µg mL , except internal 28 29 84 standards, was prepared by diluting stock solutions with ethanol. A final working solution of 30 31 -1 32 85 internal standards containing all nine internal standards at 0.1 µg mL was also prepared by diluting 33 34 86 stock solutions with ethanol.
Recommended publications
  • Bipolar Androgen Therapy (BAT) in Men with Prostate Cancer
    Bipolar Androgen Therapy (BAT) in men with prostate cancer Samuel Denmeade, MD Professor of Oncology, Urology and Pharmacology The Johns Hopkins University School of Medicine, Baltimore, MD Presentation Overview • Androgen and Androgen Signaling 101 • Rationale For Bipolar Androgen Therapy (BAT) • Results from the RESTORE study testing BAT in Castration Resistant Prostate Cancer • The multi-center TRANSFORMER Trial • Future Directions • Results of BATMAN trial testing BAT as part of Intermittent Hormone Therapy strategy Testosterone Replacement Anabolic Steroids Trenbolone Acetate (Fina-Finaplix H pellets) High Dose Testosterone as Treatment for Prostate Cancer What Are Androgens? • Steroid hormone which can bind to Androgen Receptor – Testosterone, Dihydrotestosterone (DHT), DHEA, Androstenedione… • Sexual Differentiation – Needed to make a Male (Female is Default) • Primary Sex Characteristics: – Spermatogenesis – Accessory Sex Tissue Maintenance • Penis, Prostate... • Secondary Sex Characteristics: – Bone density – Muscle mass – Libido – Hair growth – Hematopoiesis What is a Steroid Hormone? Testosterone (T) Dihydrotestosterone (DHT) Estrogen How are Androgens Made? Androgen Receptor Signaling 101 Androgen Active Androgen Receptor (Testosterone) Androgen Receptor How Do Androgens Effect the Prostate Cell? NTD- Signaling Part DBD- DNA Binding Part LBD- Androgen Binding Part Cytoplasm Cell Nucleus Binds and activates genes: -Cell Growth -Cell Survival -Make prostate stuff like PSA, Acid Phosphatase, etc. DNA The Devilish Prostate • Physiologic
    [Show full text]
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • Us Anti-Doping Agency
    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
    [Show full text]
  • Determination of 17 Hormone Residues in Milk by Ultra-High-Performance Liquid Chromatography and Triple Quadrupole Mass Spectrom
    No. LCMSMS-065E Liquid Chromatography Mass Spectrometry Determination of 17 Hormone Residues in Milk by Ultra-High-Performance Liquid Chromatography and Triple Quadrupole No. LCMSMS-65E Mass Spectrometry This application news presents a method for the determination of 17 hormone residues in milk using Shimadzu Ultra-High-Performance Liquid Chromatograph (UHPLC) LC-30A and Triple Quadrupole Mass Spectrometer LCMS- 8040. After sample pretreatment, the compounds in the milk matrix were separated using UPLC LC-30A and analyzed via Triple Quadrupole Mass Spectrometer LCMS-8040. All 17 hormones displayed good linearity within their respective concentration range, with correlation coefficient in the range of 0.9974 and 0.9999. The RSD% of retention time and peak area of 17 hormones at the low-, mid- and high- concentrations were in the range of 0.0102-0.161% and 0.563-6.55% respectively, indicating good instrument precision. Method validation was conducted and the matrix spike recovery of milk ranged between 61.00-110.9%. The limit of quantitation was 0.14-0.975 g/kg, and it meets the requirement for detection of hormones in milk. Keywords: Hormones; Milk; Solid phase extraction; Ultra performance liquid chromatograph; Triple quadrupole mass spectrometry ■ Introduction Since 2008’s melamine-tainted milk scandal, the With reference to China’s national standard GB/T adulteration of milk powder has become a major 21981-2008 "Hormone Multi-Residue Detection food safety concern. In recent years, another case of Method for Animal-derived Food - LC-MS Method", dairy product safety is suspected to cause "infant a method utilizing solid phase extraction, ultra- sexual precocity" (also known as precocious puberty) performance liquid chromatography and triple and has become another major issue challenging the quadrupole mass spectrometry was developed for dairy industry in China.
    [Show full text]
  • Pharmaceuticals and Endocrine Active Chemicals in Minnesota Lakes
    Pharmaceuticals and Endocrine Active Chemicals in Minnesota Lakes May 2013 Authors Mark Ferrey Contributors/acknowledgements The MPCA is reducing printing and mailing costs This report contains the results of a study that by using the Internet to distribute reports and characterizes the presence of unregulated information to wider audience. Visit our website contaminants in Minnesota’s lakes. The study for more information. was made possible through funding by the MPCA reports are printed on 100 percent post- Minnesota Clean Water Fund and by funding by consumer recycled content paper manufactured the U.S. Environmental Protection Agency without chlorine or chlorine derivatives. (EPA), which facilitated the sampling of lakes for this study. The Minnesota Pollution Control Agency (MPCA) thanks the following for assistance and advice in designing and carrying out this study: Steve Heiskary, Pam Anderson, Dereck Richter, Lee Engel, Amy Garcia, Will Long, Jesse Anderson, Ben Larson, and Kelly O’Hara for the long hours of sampling for this study. Cynthia Tomey, Kirsten Anderson, and Richard Grace of Axys Analytical Labs for the expert help in developing the list of analytes for this study and logistics to make it a success. Minnesota Pollution Control Agency 520 Lafayette Road North | Saint Paul, MN 55155-4194 | www.pca.state.mn.us | 651-296-6300 Toll free 800-657-3864 | TTY 651-282-5332 This report is available in alternative formats upon request, and online at www.pca.state.mn.us. Document number: tdr-g1-16 Contents Contents ...........................................................................................................................................
    [Show full text]
  • Screening of Pharmaceuticals in San Francisco Bay Wastewater
    Screening of Pharmaceuticals in San Francisco Bay Wastewater Prepared by Diana Lin Rebecca Sutton Jennifer Sun John Ross San Francisco Estuary Institute CONTRIBUTION NO. 910 / October 2018 Pharmaceuticals in Wastewater Technical Report Executive Summary Previous studies have shown that pharmaceuticals are widely detected in San Francisco Bay, and some compounds occasionally approach levels of concern for wildlife. In 2016 and 2017, seven wastewater treatment facilities located throughout the Bay Area voluntarily collected wastewater samples and funded analyses for 104 pharmaceutical compounds. This dataset represents the most comprehensive analysis of pharmaceuticals in wastewater to date in this region. On behalf of the Regional Monitoring Program for Water Quality in San Francisco Bay (RMP), the complete dataset was reviewed utilizing RMP quality assurance methods. An analysis of influent and effluent information is summarized in this report, and is intended to inform future monitoring recommendations for the Bay. Influent and effluent concentration ranges measured were generally within the same order of magnitude as other US studies, with a few exceptions for effluent. Effluent concentrations were generally significantly lower than influent concentrations, though estimated removal efficiency varied by pharmaceutical, and in some cases, by treatment type. These removal efficiencies were generally consistent with those reported in other studies in the US. Pharmaceuticals detected at the highest concentrations and with the highest frequencies in effluent were commonly used drugs, including treatments for diabetes and high blood pressure, antibiotics, diuretics, and anticonvulsants. For pharmaceuticals detected in discharged effluent, screening exercises were conducted to determine which might be appropriate candidates for further examination and potential monitoring in the Bay.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0296.191 A1 PATEL Et Al
    US 20140296.191A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0296.191 A1 PATEL et al. (43) Pub. Date: Oct. 2, 2014 (54) COMPOSITIONS OF PHARMACEUTICAL (52) U.S. Cl. ACTIVES CONTAINING DETHYLENE CPC ............... A61K 47/10 (2013.01); A61 K9/0019 GLYCOL MONOETHYLETHER OR OTHER (2013.01); A61 K9/0048 (2013.01); A61 K ALKYL DERVATIVES 45/06 (2013.01) USPC ........... 514/167: 514/177; 514/178: 514/450; (71) Applicant: THEMIS MEDICARE LIMITED, 514/334: 514/226.5: 514/449; 514/338; Mumbai (IN) 514/256; 514/570; 514/179; 514/174: 514/533; (72) Inventors: Dinesh Shantilal PATEL, Mumbai (IN); 514/629; 514/619 Sachin Dinesh PATEL, Mumbai (IN); Shashikant Prabhudas KURANI, Mumbai (IN); Madhavlal Govindlal (57) ABSTRACT PATEL, Mumbai (IN) (73) Assignee: THEMIS MEDICARE LIMITED, The present invention relates to pharmaceutical compositions Mumbai (IN) of various pharmaceutical actives, especially lyophilic and hydrophilic actives containing Diethylene glycol monoethyl (21) Appl. No.: 14/242,973 ether or other alkyl derivatives thereofas a primary vehicle and/or to pharmaceutical compositions utilizing Diethylene (22) Filed: Apr. 2, 2014 glycol monoethyl ether or other alkyl derivatives thereofas a primary vehicle or as a solvent system in preparation of Such (30) Foreign Application Priority Data pharmaceutical compositions. The pharmaceutical composi Apr. 2, 2013 (IN) ......................... 1287/MUMA2013 tions of the present invention are safe, non-toxic, exhibits enhanced physical stability compared to conventional formu Publication Classification lations containing such pharmaceutical actives and are Suit able for use as injectables for intravenous and intramuscular (51) Int. Cl. administration, as well as for use as a preformed solution/ A647/ (2006.01) liquid for filling in and preparation of capsules, tablets, nasal A6 IK 45/06 (2006.01) sprays, gargles, dermal applications, gels, topicals, liquid oral A6 IK9/00 (2006.01) dosage forms and other dosage forms.
    [Show full text]
  • Trenbolone Acetate Formulation
    SAFETY DATA SHEET Trenbolone Acetate Formulation Version Revision Date: SDS Number: Date of last issue: 2020/10/10 3.2 2021/04/09 916795-00012 Date of first issue: 2016/09/30 1. PRODUCT AND COMPANY IDENTIFICATION Chemical product name : Trenbolone Acetate Formulation Supplier's company name, address and phone number Company name of supplier : MSD Address : Kumagaya, Saitama Prefecture , Xicheng 810 MSD Co., Ltd. Menuma factory Telephone : 048-588-8411 E-mail address : [email protected] Emergency telephone number : +1-908-423-6000 Recommended use of the chemical and restrictions on use Recommended use : Veterinary product 2. HAZARDS IDENTIFICATION GHS classification of chemical product Carcinogenicity : Category 2 Reproductive toxicity : Category 2 Specific target organ toxicity - : Category 1 (Endocrine system, Blood) repeated exposure (Oral) Long-term (chronic) aquatic : Category 1 hazard GHS label elements Hazard pictograms : Signal word : Danger Hazard statements : H351 Suspected of causing cancer. H361fd Suspected of damaging fertility. Suspected of damag- ing the unborn child. H372 Causes damage to organs (Endocrine system, Blood) through prolonged or repeated exposure if swallowed. H410 Very toxic to aquatic life with long lasting effects. Precautionary statements : Prevention: P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. 1 / 18 SAFETY DATA SHEET Trenbolone Acetate Formulation Version Revision Date: SDS Number: Date of last issue: 2020/10/10 3.2 2021/04/09 916795-00012 Date of first issue: 2016/09/30 P260 Do not breathe dust. P264 Wash skin thoroughly after handling. P270 Do not eat, drink or smoke when using this product.
    [Show full text]
  • Effects of Androgenic-Anabolic Steroids on Apolipoproteins and Lipoprotein (A) F Hartgens, G Rietjens, H a Keizer, H Kuipers, B H R Wolffenbuttel
    253 ORIGINAL ARTICLE Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a) F Hartgens, G Rietjens, H A Keizer, H Kuipers, B H R Wolffenbuttel ............................................................................................................................... Br J Sports Med 2004;38:253–259. doi: 10.1136/bjsm.2003.000199 Objectives: To investigate the effects of two different regimens of androgenic-anabolic steroid (AAS) administration on serum lipid and lipoproteins, and recovery of these variables after drug cessation, as indicators of the risk for cardiovascular disease in healthy male strength athletes. Methods: In a non-blinded study (study 1) serum lipoproteins and lipids were assessed in 19 subjects who self administered AASs for eight or 14 weeks, and in 16 non-using volunteers. In a randomised double blind, placebo controlled design, the effects of intramuscular administration of nandrolone decanoate (200 mg/week) for eight weeks on the same variables in 16 bodybuilders were studied (study 2). Fasting serum concentrations of total cholesterol, triglycerides, HDL-cholesterol (HDL-C), HDL2-cholesterol (HDL2- C), HDL3-cholesterol (HDL3-C), apolipoprotein A1 (Apo-A1), apolipoprotein B (Apo-B), and lipoprotein (a) (Lp(a)) were determined. Results: In study 1 AAS administration led to decreases in serum concentrations of HDL-C (from 1.08 (0.30) to 0.43 (0.22) mmol/l), HDL2-C (from 0.21 (0.18) to 0.05 (0.03) mmol/l), HDL3-C (from 0.87 (0.24) to 0.40 (0.20) mmol/l, and Apo-A1 (from 1.41 (0.27) to 0.71 (0.34) g/l), whereas Apo-B increased from 0.96 (0.13) to 1.32 (0.28) g/l.
    [Show full text]
  • Muscle, Poultry Liver, Water and Fish
    TITLE : MUSCLE, POULTRY LIVE R, WATER AND FISH - THE SCREENING, QUANTIFICATION AND CONFIRMATION OF A SELECTION OF GROWTH PROMOTORS - LC-MS/MS 1 OBJECTIVE AND SCOPE This SOP describes the analysis using LC-MS/MS of a selection of growth-promoting compounds in muscle, poultry liver, water and fish. These compounds are: 17 α–trenbolone, 17β–trenbolone, 17 α-nortestosterone, 17 β- nortestosterone, androsta-1,4-diene-3,17-dione (ADD), 17 α–boldenone, 17 β-boldenone, methylboldenone, 17 α- testosterone, 17 β-testosterone, 17 α-methyltestosterone, 16 β-OH-stanozolol, stanozolol, prednisolone, methylprednisolone, isoflupredone, flumethasone, dexamethasone, betamethasone, triamcinolon-acetonide, clobetasol, megestrol-acetate, melengestrol-acetate, medroxyprogesterone-acetate, chlormadinone-acetate, α- zeranol ( α-zearalanol), β-zeranol ( β-zearalanol), zearalanon, zearalenon, α-zearalenol, β-zearalenol. Bovine muscle is fully validated, other muscle, poultry liver, water and fish are partially validated. The method has a measuring range of 0.2 to 5.0 µg/kg. 2 DEFINITION MMS Matrix matched standards ES Electrospray MS Mass spectrometer UPLC Ultra Performance Liquid Chromatography ADD Androsta-1,4-diene-3,17-dione SPE Solid Phase Extraction ACN Acetonitrile MeOH Methanol FA Formic acid (HCOOH) Water MilliQ H2O DMSO Dimethyl sulfoxide HAc Acetic acid NH3 Ammonia 3 PRINCIPLE The method consists of the following steps: • Destruction of meat with a bead ruptor • Extraction of analytes from destructed meat • Sample clean-up with 96-wells SPE • Analysis with LC-MSMS 4 CHEMICALS AND REAGENTS All reagents and chemicals must be at least pro analysis quality. With ‘water’ is meant water, purified with a MilliQ® system with a minimum resistance of at least 18.2 M Ω.cm -1.
    [Show full text]
  • NEWS 02 2020 ENG.Qxp Layout 1
    Polymers and fluorescence Balance of power 360° drinking water analysis trilogy Fluorescence spectroscopy LCMS-8060NX: performance of industrial base polymers and robustness without Automatic, simultaneous and compromising sensitivity rapid analysis of pesticides and speed CONTENT APPLICATION »Plug und Play« disease screening solution? – The MALDI-8020 in screening for Sickle Cell Disease 4 Customized software solutions for any measurement – Macro programming for Shimadzu UV-Vis and FTIR 8 Ensuring steroid-free food supplements – Identification of steroids in pharmaceuticals and food supplements with LCMS-8045 11 MSn analysis of nonderivatized and Mtpp-derivatized peptides – Two recent studies applying LCMS-IT-TOF instruments 18 Polymers and fluorescence – Part 2: How much fluorescence does a polymer show during quality control? 26 PRODUCTS The balance of power – LCMS-8060NX balances enhanced performance and robustness 7 360° drinking water analysis: Episode 2 – Automatic, simul- taneous and rapid analysis of pesticides in drinking water by online SPE and UHPLC-MS/MS 14 Versatile testing tool for the automotive industry – Enrico Davoli with the PESI-MS system (research-use only [RUO] instrument) New HMV-G3 Series 17 No more headaches! A guide to choosing the perfect C18 column 22 Validated method for monoclonal antibody drugs – Assessment of the nSMOL methodology in Global solution through the validation of bevacizumab in human serum 24 global collaboration LATEST NEWS Global solution through global collaboration – Shimadzu Cancer diagnosis:
    [Show full text]
  • 2019 Prohibited List
    THE WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST JANUARY 2019 The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2019 SUBSTANCES & METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4, S4.5, S6.A, AND PROHIBITED METHODS M1, M2 AND M3. PROHIBITED SUBSTANCES NON-APPROVED SUBSTANCES Mestanolone; S0 Mesterolone; Any pharmacological substance which is not Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien- addressed by any of the subsequent sections of the 3-one); List and with no current approval by any governmental Metenolone; regulatory health authority for human therapeutic use Methandriol; (e.g. drugs under pre-clinical or clinical development Methasterone (17β-hydroxy-2α,17α-dimethyl-5α- or discontinued, designer drugs, substances approved androstan-3-one); only for veterinary use) is prohibited at all times. Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien- 3-one); ANABOLIC AGENTS Methyl-1-testosterone (17β-hydroxy-17α-methyl-5α- S1 androst-1-en-3-one); Anabolic agents are prohibited. Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en- 3-one); 1. ANABOLIC ANDROGENIC STEROIDS (AAS) Methyltestosterone; a. Exogenous*
    [Show full text]